<DOC>
	<DOCNO>NCT02262143</DOCNO>
	<brief_summary>Efficacy safety combination therapy rosuvastatin fenofibrate versus rosuvastatin monotherapy mixed dyslipidemia patient : A randomized , multi-center , double-blind , phase 3 study</brief_summary>
	<brief_title>Phase III Study Rosuvastatin Fenofibrate Versus Rosuvastatin Mixed Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>19 ~ 80 year old High risk patient Coronary Heart Disease At Visit 1 ( Screening ) 1 . Treated Rosuvastatin 10mg monotherapy 4weeks prior study 2 . 110 mg/dl ≥ LDLC , 200 mg/dl ≤ TG ≤ 500 mg/dl At Visit 2 ( Baseline ) , 110 mg/dl ≥ LDLC , 200 mg/dl ≤ TG ≤ 500 mg/dl AST ALT &gt; 2X ULN Patients uncontrolled hyperthyroidism ( TSH &gt; 1.5X ULN ) Patients uncontrolled diabetes ( HbA1c ≥ 9 % ) Patients uncontrolled hypertension ( SBP &gt; 160mmHg DBP &gt; 95mmHg ) Patients congestive heart failure ( NYHA class III~IV ) uncontrolled arrhythmia within 6 month Patients treat investigational drug within 3 month time consent obtain Not eligible participate study discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>